LOGIN  |  REGISTER
Assertio

Tactile Medical to Participate in Upcoming Investor Conferences in February and March

February 05, 2024 | Last Trade: US$29.57 0.03 0.10

MINNEAPOLIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:

The BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference at the Cliff Lodge in Snowbird, UT.

  • Management will participate in investor meetings on Tuesday, February 13th. There will be no formal presentation to investors.

The Oppenheimer 34th Annual Healthcare MedTech & Services Conference which is being held virtually.

  • Management will participate in a virtual fireside chat at 2:40 p.m. Eastern Time on Tuesday, March 12th.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page